APMD net income rises to $193.7M in H1 2026
APMD reported net income of $193.7M for the first half of 2026, driven by SASS divestiture gains. R&D expenses fell as Phase 3 trials for Oxnimbi concluded. Cash was $172.8M pre-IPO and $200.4M raised in August.
Story updates
09:16:52 PM UTC
SquawkNews
FDA accepted the NDA for Oxnimbi, with a PDUFA date set for February 2027. Q2 2026 saw a net income of $125.9 million, driven by asset monetization and IPO proceeds, while commercial readiness for Oxnimbi advances amid a large unmet OSA market.Original document: Apnimed, Inc. [APMD] SEC 8-K Current…
7M in the first half of 2026, helped by the SASS divestiture and related gains, while research and development expenses declined after Phase 3 trials for Oxnimbi were completed. 4M in August, leaving it positioned to fund operations through mid-2028.